Compared with ipilimumab, ipilimumab plus anti-PD-1therapy for patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy showed ICERs below the WTP threshold of $150,000/QALY in the majority of the subgroups (Table 3). Here, CD274 is linked to metastatic melanoma.